Parkinson’s disease - Pipeline Insight, 2025
Description
DelveInsight’s, “Parkinson’s disease - Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Parkinson’s disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Parkinson’s disease: Overview
Parkinson's disease (PD) is a progressive neurodegenerative disorder mainly impacting dopamine-producing neurons in the substantia nigra, a critical region in the brain responsible for movement control. As these neurons degenerate, dopamine levels decrease, leading to symptoms like tremors, stiffness, and difficulty with balance and coordination. PD affects both motor and non-motor functions, gradually impairing the patient's quality of life. The exact cause of neuronal loss in PD remains largely unknown, though genetics and environmental factors may play a role. Parkinson's disease presents with four main symptoms: tremors (shaking) in the hands, arms, legs, jaw, or head; stiffness in the limbs and trunk; slowness of movement; and impaired balance and coordination, which can lead to falls. Additional symptoms may include depression, emotional changes, trouble swallowing, speaking difficulties, urinary or digestive issues, skin problems, and sleep disruptions. The onset of Parkinson’s symptoms is subtle and gradual, often mistaken for normal aging. People may initially experience mild tremors, difficulty rising from a chair, soft speech, or small, cramped handwriting.
There is no “one way” to diagnose Parkinson’s disease (PD). However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s — particularly in its early stages — is difficult, but a skilled practitioner can come to a reasoned conclusion that it is PD. People with Parkinson's-like symptoms that result from other causes are sometimes said to have parkinsonism. While these disorders initially may be misdiagnosed as Parkinson's, certain medical tests, as well as response to drug treatment, may help to distinguish them from Parkinson's.
Although Parkinson's disease cannot be cured, treatments such as medications, surgical procedures, and various therapies can effectively relieve some symptoms. The primary treatment is levodopa (L-dopa), a drug that nerve cells in the brain use to produce dopamine, thus helping to replenish its dwindling levels and reduce symptoms like tremors and muscle stiffness. Levodopa is often paired with carbidopa, another medication that enhances levodopa’s effectiveness by preventing its early breakdown in the bloodstream, ensuring more reaches the brain. Carbidopa also helps to reduce some of levodopa's side effects, including nausea, vomiting, low blood pressure, and restlessness, which allows for a lower dosage of levodopa to be used. For individuals with more advanced symptoms, options like deep brain stimulation (DBS) and physical, occupational, and speech therapy are also available, often improving mobility, speech, and overall quality of life.
""Parkinson’s disease- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s disease pipeline landscape is provided which includes the disease overview and Parkinson’s disease treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Parkinson’s disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Parkinson’s disease Emerging Drugs
Further product details are provided in the report……..
Parkinson’s disease: Therapeutic Assessment
This segment of the report provides insights about the different Parkinson’s disease drugs segregated based on following parameters that define the scope of the report, such as:
Parkinson’s disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Parkinson’s disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s disease drugs.
Parkinson’s disease Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Parkinson’s disease: Overview
Parkinson's disease (PD) is a progressive neurodegenerative disorder mainly impacting dopamine-producing neurons in the substantia nigra, a critical region in the brain responsible for movement control. As these neurons degenerate, dopamine levels decrease, leading to symptoms like tremors, stiffness, and difficulty with balance and coordination. PD affects both motor and non-motor functions, gradually impairing the patient's quality of life. The exact cause of neuronal loss in PD remains largely unknown, though genetics and environmental factors may play a role. Parkinson's disease presents with four main symptoms: tremors (shaking) in the hands, arms, legs, jaw, or head; stiffness in the limbs and trunk; slowness of movement; and impaired balance and coordination, which can lead to falls. Additional symptoms may include depression, emotional changes, trouble swallowing, speaking difficulties, urinary or digestive issues, skin problems, and sleep disruptions. The onset of Parkinson’s symptoms is subtle and gradual, often mistaken for normal aging. People may initially experience mild tremors, difficulty rising from a chair, soft speech, or small, cramped handwriting.
There is no “one way” to diagnose Parkinson’s disease (PD). However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s — particularly in its early stages — is difficult, but a skilled practitioner can come to a reasoned conclusion that it is PD. People with Parkinson's-like symptoms that result from other causes are sometimes said to have parkinsonism. While these disorders initially may be misdiagnosed as Parkinson's, certain medical tests, as well as response to drug treatment, may help to distinguish them from Parkinson's.
Although Parkinson's disease cannot be cured, treatments such as medications, surgical procedures, and various therapies can effectively relieve some symptoms. The primary treatment is levodopa (L-dopa), a drug that nerve cells in the brain use to produce dopamine, thus helping to replenish its dwindling levels and reduce symptoms like tremors and muscle stiffness. Levodopa is often paired with carbidopa, another medication that enhances levodopa’s effectiveness by preventing its early breakdown in the bloodstream, ensuring more reaches the brain. Carbidopa also helps to reduce some of levodopa's side effects, including nausea, vomiting, low blood pressure, and restlessness, which allows for a lower dosage of levodopa to be used. For individuals with more advanced symptoms, options like deep brain stimulation (DBS) and physical, occupational, and speech therapy are also available, often improving mobility, speech, and overall quality of life.
""Parkinson’s disease- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s disease pipeline landscape is provided which includes the disease overview and Parkinson’s disease treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson’s disease R&D. The therapies under development are focused on novel approaches to treat/improve Parkinson’s disease.
This segment of the Parkinson’s disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Parkinson’s disease Emerging Drugs
- Tavapadon: AbbVie
- KM-819: FAScinate Therapeutics
- UCB0022: UCB Biopharma
- Lu AF28996: Lundbeck A/S
- LBT-3627: Longevity Biotech
Further product details are provided in the report……..
Parkinson’s disease: Therapeutic Assessment
This segment of the report provides insights about the different Parkinson’s disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Parkinson’s disease
- There are approx. 80+ key companies which are developing the therapies for Parkinson’s disease. The companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. Phase II include, AbbVie.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Parkinson’s disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Parkinson’s disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s disease drugs.
Parkinson’s disease Report Insights
- Parkinson’s disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Parkinson’s disease drugs?
- How many Parkinson’s disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Parkinson’s disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Parkinson’s disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Parkinson’s disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- AbbVie
- Pharma Two B Ltd.
- UCB Biopharma
- Ventyx Biosciences
- FAScinate Therapeutics
- Longevity Biotech
- Lundbeck A/S
- iCamuno Biotherapeutics
- Neuropore Therapies
- Tavapadon
- P2B001
- UCB0022
- VTX3232
- KM-819
- LBT-3627
- Lu AF-28996
- ICA07
- NPT1220-478
Table of Contents
280 Pages
- Introduction
- Executive Summary
- Parkinson’s disease: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Parkinson’s disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Tavapadon: AbbVie
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- KM-819: FAScinate Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Lu AF28996: Lundbeck A/S
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- ICA07: iCamuno Biotherapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Parkinson’s disease Key Companies
- Parkinson’s disease Key Products
- Parkinson’s disease- Unmet Needs
- Parkinson’s disease- Market Drivers and Barriers
- Parkinson’s disease- Future Perspectives and Conclusion
- Parkinson’s disease Analyst Views
- Parkinson’s disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
